ArticlePLoS computational biology2025
Automated and modular protein binder design with BinderFlow.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Agentic campaign control for high-throughput de novo binder design.bioRxiv : the preprint server for biology · 2026Article
- ProteinDJ: A high-performance and modular protein design pipeline.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Deep learning has revolutionised de novo protein design, with new models achieving unprecedented success in creating novel proteins with specific functions, including artificial protein binders. However, current workflows remain computationally demanding and challenging to operate without dedicated infrastructure and expertise. To overcome these limitations, we present BinderFlow, an open, structured, and parallelised pipeline that automates end-to-end protein binder design. Its batch-based architecture enables live monitoring of design campaigns, seamless coexistence with other GPU-intensive processes, and minimal user intervention. BinderFlow's modular design facilitates the integration of new tools, allowing rapid adaptation to emerging methods. We demonstrate its utility by running automated design campaigns that rapidly generate diverse, high-confidence candidates suitable for experimental validation. To complement the pipeline, we developed BFmonitor, a web-based dashboard for real-time campaign monitoring, design evaluation, and hit selection. Together, BinderFlow and BFmonitor make generative protein design more accessible, scalable, and reproducible, streamlining both exploratory and production-level research. The software is freely available at https://github.com/cryoEM-CNIO/BinderFlow under the GNU LGPL v3.0 license.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.